FDA expands Cabozantinib approval to include liver cancer — 4 insights

The FDA approved Cabozantinib for use in patients with liver cancer, Medscape reports. The drug was already approved for thyroid and renal cancer patients.

What you should know:

1. Cabozantinib can now be used in patients with hepatocellular carcinoma who were previously treated with sorafenib.

2. Cabozantinib is an orally-delivered drug which inhibits multiple receptors involved in cell function.

3. The FDA first approved the drug in 2012 as a treatment for thyroid cancer. The FDA approved the drug as a renal cancer treatment in 2016.

4. The FDA approved the drug for liver cancer patients based on a phase 3 study. In the study, patients treated with Cabozantinib saw their median survival rate increase 2.2 months.

More articles on gastroenterology: 
What GI practices should look for in a PE partner — 5 Qs with Provident's Abe M'Bodj
84 regional income, case mix benchmarks for ASCs to know
Why an Oklahoma-based ASC values autonomy — 3 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months